Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies | Genetics and Genomics | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Greco  FA, Hainsworth  JD. Cancer of unknown primary. In: DeVita  TV, Hellman  S, Rosenberg  SA, eds.  Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Wolters, Kluwer/Lippincott, Williams and Wilkins; 2011:2033-2051.
2.
Stella  GM, Senetta  R, Cassenti  A, Ronco  M, Cassoni  P.  Cancers of unknown primary origin: current perspectives and future therapeutic strategies.  J Transl Med. 2012;10:12.PubMedGoogle ScholarCrossref
3.
Pavlidis  N, Pentheroudakis  G.  Cancer of unknown primary site.  Lancet. 2012;379(9824):1428-1435.PubMedGoogle ScholarCrossref
4.
Massard  C, Loriot  Y, Fizazi  K.  Carcinomas of an unknown primary origin—diagnosis and treatment.  Nat Rev Clin Oncol. 2011;8(12):701-710.PubMedGoogle ScholarCrossref
5.
Varadhachary  GR, Raber  MN.  Cancer of unknown primary site.  N Engl J Med. 2014;371(8):757-765.PubMedGoogle ScholarCrossref
6.
Petrakis  D, Pentheroudakis  G, Voulgaris  E, Pavlidis  N.  Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature.  Cancer Treat Rev. 2013;39(7):701-708.PubMedGoogle ScholarCrossref
7.
Kamposioras  K, Pentheroudakis  G, Pavlidis  N.  Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks.  Eur J Clin Invest. 2013;43(5):491-500.PubMedGoogle ScholarCrossref
8.
Greco  FA, Oien  K, Erlander  M,  et al.  Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes.  Ann Oncol. 2012;23(2):298-304.PubMedGoogle ScholarCrossref
9.
Tothill  RW, Li  J, Mileshkin  L,  et al.  Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.  J Pathol. 2013;231(4):413-423.PubMedGoogle ScholarCrossref
10.
Savas  P, Hughes  B, Solomon  B.  Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.  J Thorac Dis. 2013;5(suppl 5):S579-S592.PubMedGoogle Scholar
11.
Frampton  GM, Fichtenholtz  A, Otto  GA,  et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.  Nat Biotechnol. 2013;31(11):1023-1031.PubMedGoogle ScholarCrossref
12.
Forbes  SA, Bindal  N, Bamford  S,  et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.  Nucleic Acids Res. 2011;39(Database issue):D945-D950.PubMedGoogle ScholarCrossref
13.
Compeau  PE, Pevzner  PA, Tesler  G.  How to apply de Bruijn graphs to genome assembly.  Nat Biotechnol. 2011;29(11):987-991.PubMedGoogle ScholarCrossref
14.
Mazières  J, Peters  S, Lepage  B,  et al.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.  J Clin Oncol. 2013;31(16):1997-2003.PubMedGoogle ScholarCrossref
15.
Ali  SM, Alpaugh  RK, Downing  SR,  et al.  Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.  J Clin Oncol. 2014;32(25):e88-e91.PubMedGoogle ScholarCrossref
16.
Schwab  R, Petak  I, Kollar  M,  et al.  Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.  Lung Cancer. 2014;83(1):109-111.PubMedGoogle ScholarCrossref
17.
Palma  NA, Ali  SM, O’Connor  J,  et al.  Durable response to crizotinib in a MET-amplified, KRAS-mutated carcinoma of unknown primary.  Case Rep Oncol. 2014;7(2):503-508.PubMedGoogle ScholarCrossref
18.
Chung  JH, Ali  SM, Davis  J,  et al.  A poorly differentiated malignant neoplasm lacking lung markers harbors an EML4-ALK rearrangement and responds to crizotinib.  Case Rep Oncol. 2014;7(3):628-632.PubMedGoogle ScholarCrossref
19.
Garber  K.  Ready or not: personal tumor profiling tests take off.  J Natl Cancer Inst. 2011;103(2):84-86.PubMedGoogle ScholarCrossref
20.
Kim  KW, Krajewski  KM, Jagannathan  JP,  et al.  Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know.  AJR Am J Roentgenol. 2013;200(3):484-492.PubMedGoogle ScholarCrossref
21.
Taylor  MB, Bromham  NR, Arnold  SE.  Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines.  Br J Radiol. 2012;85(1014):661-671.PubMedGoogle ScholarCrossref
22.
Kwee  TC, Basu  S, Cheng  G, Alavi  A.  FDG PET/CT in carcinoma of unknown primary.  Eur J Nucl Med Mol Imaging. 2010;37(3):635-644.PubMedGoogle ScholarCrossref
23.
Morawietz  L, Floore  A, Stork-Sloots  L,  et al.  Comparison of histopathological and gene expression-based typing of cancer of unknown primary.  Virchows Arch. 2010;456(1):23-29.PubMedGoogle ScholarCrossref
24.
Oien  KA, Dennis  JL.  Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling.  Ann Oncol. 2012;23(suppl 10):x271-x277.PubMedGoogle ScholarCrossref
25.
Rossi  G, Nannini  N, Costantini  M.  Morphology and more specific immunohistochemical stains are fundamental prerequisites in detection of unknown primary cancer.  J Clin Oncol. 2009;27(4):649-650.PubMedGoogle ScholarCrossref
26.
Ponce Lorenzo  J, Segura Huerta  A, Díaz Beveridge  R,  et al.  Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables.  Clin Transl Oncol. 2007;9(7):452-458.PubMedGoogle ScholarCrossref
27.
Milović  M, Popov  I, Jelić  S.  Tumor markers in metastatic disease from cancer of unknown primary origin.  Med Sci Monit. 2002;8(2):MT25-MT30.PubMedGoogle Scholar
28.
Greco  FA, Lennington  WJ, Spigel  DR, Hainsworth  JD.  Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.  J Natl Cancer Inst. 2013;105(11):782-790.PubMedGoogle ScholarCrossref
29.
Varadhachary  G.  New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.  Clin Cancer Res. 2013;19(15):4027-4033.PubMedGoogle ScholarCrossref
30.
Pentheroudakis  G, Greco  FA, Pavlidis  N.  Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.  Cancer Treat Rev. 2009;35(3):221-227.PubMedGoogle ScholarCrossref
31.
Hainsworth  JD, Rubin  MS, Spigel  DR,  et al.  Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.  J Clin Oncol. 2013;31(2):217-223.PubMedGoogle ScholarCrossref
32.
Motzer  RJ, Rodriguez  E, Reuter  VE, Bosl  GJ, Mazumdar  M, Chaganti  RS.  Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.  J Clin Oncol. 1995;13(1):274-282.PubMedGoogle ScholarCrossref
33.
Meiri  E, Mueller  WC, Rosenwald  S,  et al.  A second-generation microRNA-based assay for diagnosing tumor tissue origin.  Oncologist. 2012;17(6):801-812.PubMedGoogle ScholarCrossref
34.
Pavlidis  N, Briassoulis  E, Bai  M, Fountzilas  G, Agnantis  N.  Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin.  Anticancer Res. 1995;15(6B):2563-2567.PubMedGoogle Scholar
35.
Golubovskaya  VM, Cance  WG.  Targeting the p53 pathway.  Surg Oncol Clin N Am. 2013;22(4):747-764.PubMedGoogle ScholarCrossref
36.
Bar-Eli  M, Abbruzzese  JL, Lee-Jackson  D, Frost  P.  p53 gene mutation spectrum in human unknown primary tumors.  Anticancer Res. 1993;13(5A):1619-1623.PubMedGoogle Scholar
37.
Massard  C, Voigt  JJ, Laplanche  A,  et al.  Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?  Br J Cancer. 2007;97(7):857-861.PubMedGoogle ScholarCrossref
38.
Dova  L, Pentheroudakis  G, Georgiou  I,  et al.  Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?  Clin Exp Metastasis. 2007;24(2):79-86.PubMedGoogle ScholarCrossref
39.
Montemurro  F, Scaltriti  M.  Biomarkers of drugs targeting HER-family signalling in cancer.  J Pathol. 2014;232(2):219-229.PubMedGoogle ScholarCrossref
40.
Weinstein  JN, Collisson  EA, Mills  GB,  et al; Cancer Genome Atlas Research Network.  The Cancer Genome Atlas Pan-Cancer analysis project.  Nat Genet. 2013;45(10):1113-1120.PubMedGoogle ScholarCrossref
41.
Kümler  I, Tuxen  MK, Nielsen  DL.  A systematic review of dual targeting in HER2-positive breast cancer.  Cancer Treat Rev. 2014;40(2):259-270.PubMedGoogle ScholarCrossref
42.
Ohta  S, Cho  Y, Shibata  M,  et al.  Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules.  Exp Ther Med. 2012;3(3):547-549.PubMedGoogle ScholarCrossref
43.
Vornicova  O, Hershkovitz  D, Yablonski-Peretz  T, Ben-Itzhak  O, Keidar  Z, Bar-Sela  G.  Treatment of metastatic extramammary Paget’s disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.  Oncologist. 2014;19(9):1006-1007.PubMedGoogle ScholarCrossref
44.
Luke  JJ, Schwartz  GK.  Chemotherapy in the management of advanced cutaneous malignant melanoma.  Clin Dermatol. 2013;31(3):290-297.PubMedGoogle ScholarCrossref
45.
Lipson  D, Capelletti  M, Yelensky  R,  et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.  Nat Med. 2012;18(3):382-384.PubMedGoogle ScholarCrossref
46.
Drilon  A, Wang  L, Hasanovic  A,  et al.  Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas.  Cancer Discov. 2013;3(6):630-635.PubMedGoogle ScholarCrossref
47.
Sim  MW, Cohen  MS.  The discovery and development of vandetanib for the treatment of thyroid cancer.  Expert Opin Drug Discov. 2014;9(1):105-114.PubMedGoogle ScholarCrossref
48.
Krikelis  D, Pentheroudakis  G, Goussia  A,  et al.  Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.  Clin Exp Metastasis. 2012;29(6):603-614.PubMedGoogle ScholarCrossref
49.
Stella  GM, Benvenuti  S, Comoglio  PM.  Targeting the MET oncogene in cancer and metastases.  Expert Opin Investig Drugs. 2010;19(11):1381-1394.PubMedGoogle ScholarCrossref
50.
Stella  GM, Benvenuti  S, Gramaglia  D,  et al.  MET mutations in cancers of unknown primary origin (CUPs).  Hum Mutat. 2011;32(1):44-50.PubMedGoogle ScholarCrossref
51.
Ross  JS, Cronin  M.  Whole cancer genome sequencing by next-generation methods.  Am J Clin Pathol. 2011;136(4):527-539.PubMedGoogle ScholarCrossref
52.
Wagle  N, Berger  MF, Davis  MJ,  et al.  High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.  Cancer Discov. 2012;2(1):82-93.PubMedGoogle ScholarCrossref
53.
Tran  B, Brown  AM, Bedard  PL,  et al.  Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.  Int J Cancer. 2013;132(7):1547-1555.PubMedGoogle ScholarCrossref
54.
Bugat  R, Bataillard  A, Lesimple  T,  et al; FNCLCC.  Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002).  Br J Cancer. 2003;89(suppl 1):S59-S66.PubMedGoogle ScholarCrossref
55.
Hainsworth  JD, Spigel  DR, Burris  HA  III,  et al.  Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.  Cancer. 2010;116(10):2448-2454.PubMedGoogle Scholar
56.
Fizazi  K, Greco  FA, Pavlidis  N, Pentheroudakis  G; ESMO Guidelines Working Group.  Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2011;22(suppl 6):vi64-vi68.PubMedGoogle ScholarCrossref
57.
Golfinopoulos  V, Pentheroudakis  G, Salanti  G, Nearchou  AD, Ioannidis  JP, Pavlidis  N.  Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis.  Cancer Treat Rev. 2009;35(7):570-573.PubMedGoogle ScholarCrossref
58.
Greco  FA.  The impact of molecular testing on treatment of cancer of unknown primary origin.  Oncology (Williston Park). 2013;27(8):815-817.PubMedGoogle Scholar
59.
Schwartz  AM, Harpaz  N.  A primary approach to cancers of unknown primary.  J Natl Cancer Inst. 2013;105(11):759-761.PubMedGoogle ScholarCrossref
60.
Kandoth  C, McLellan  MD, Vandin  F,  et al.  Mutational landscape and significance across 12 major cancer types.  Nature. 2013;502(7471):333-339.PubMedGoogle ScholarCrossref
61.
Collins  FS, Hamburg  MA.  First FDA authorization for next-generation sequencer.  N Engl J Med. 2013;369(25):2369-2371.PubMedGoogle ScholarCrossref
Original Investigation
February 12, 2015

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies

Author Affiliations
  • 1Foundation Medicine Inc, Cambridge, Massachusetts
  • 2Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York
JAMA Oncol. 2015;1(1):40-49. doi:10.1001/jamaoncol.2014.216
Abstract

Importance  For carcinoma of unknown primary site (CUP), determining the primary tumor site may be uninformative and often does not improve outcome.

Objective  To discover opportunities for targeted therapies in patients with CUP not currently searched for in routine practice.

Design, Setting, and Participants  Comprehensive genomic profiling on 200 CUP formalin-fixed paraffin-embedded specimens (mean, 756× coverage) using the hybrid-capture–based FoundationOne assay at academic and community oncology clinics.

Main Outcomes and Measures  Presence of targetable genomic alterations (GAs) in CUP and responses to targeted therapies.

Results  There were 125 adenocarcinomas of unknown primary site (ACUPs) and 75 carcinomas of unknown primary site without features of adenocarcinoma (non-ACUPs). At least 1 GA was found in 192 (96%) of CUP specimens, with a mean (SD) of 4.2 (2.8) GAs per tumor. The most frequent GAs were in TP53 (110 [55%]), KRAS (40 [20%]), CDKN2A (37 [19%]), MYC (23 [12%]), ARID1A (21 [11%]), MCL1 (19 [10%]), PIK3CA (17 [9%]), ERBB2 (16 [8%]), PTEN (14 [7%]), EGFR (12 [6%]), SMAD4 (13 [7%]), STK11 (13 [7%]), SMARCA4 (12 [6%]), RB1 (12 [6%]), RICTOR (12 [6%]), MLL2 (12 [6%]), BRAF (11 [6%]), and BRCA2 (11 [6%]). One or more potentially targetable GAs were identified in 169 of 200 (85%) CUP specimens. Mutations or amplifications of ERBB2 were more frequent in ACUPs (13 [10%]) than in non-ACUPs (3 [4%]). Alterations of EGFR (10 [8%] vs 2 [3%]) and BRAF (8 [6%] vs 3 [4%]) were more common in ACUPs than in non-ACUPs. Strikingly, clinically relevant alterations in the receptor tyrosine kinase (RTK)/Ras signaling pathway including alterations in ALK, ARAF, BRAF, EGFR, FGFR1, FGFR2, KIT, KRAS, MAP2K1, MET, NF1, NF2, NRAS, RAF1, RET, and ROS1 were found in 90 (72%) ACUPs but in only 29 (39%) non-ACUPs (P < .001).

Conclusions and Relevance  Almost all CUP samples harbored at least 1 clinically relevant GA with potential to influence and personalize therapy. The ACUP tumors were more frequently driven by GAs in the highly druggable RTK/Ras/mitogen-activated protein kinase (MAPK) signaling pathway than the non-ACUP tumors. Comprehensive genomic profiling can identify novel treatment paradigms to address the limited options and poor prognoses of patients with CUP.

×